Malignant pleural mesothelioma: A new standard of care

Lung Cancer

Volumn 54, Issue SUPPL. 2, 2006, Pages

  Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Asbestos; Chemotherapy; Lung cancer; Mesothelioma; Pneumonectomy

Indexed keywords

ALANOSINE; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FOLIC ACID; IMATINIB; METHOTREXATE; MITOMYCIN; PEMETREXED; SEMAXANIB; SORAFENIB; SUBEROYLANILIDE HYDROXAMIC ACID; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; TRIMETREXATE; VATALANIB; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; HUMAN; INCIDENCE; LUNG RESECTION; MALIGNANT PLEURAL MESOTHELIOMA; NAUSEA AND VOMITING; PLEURA CAVITY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PNEUMONECTOMY; TREATMENT OUTCOME;

EID: 33750620348     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.09.011     Document Type: Article

References (39)

1. Pelucchi C., Malvezzi M., La Vecchia C., Levi F., Decarli A., and Negri E. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 90 (2004) 1022-1024
2. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., and Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92 (2005) 587-593
3. Peto J., Decarli A., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672
4. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 49 (2005) S3-S8
5. Altomare D.A., Vaslet C.A., Skele K.L., De Rienzo A., Devarajan K., Jhanwar S.C., et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65 (2005) 8090-8095
6. Prins J.B., Williamson K.A., Kamp M.M., Van Hezik E.J., Van der Kwast T.H., Hagemeijer A., et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75 (1998) 649-653
7. Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55 (1995) 1227-1231
8. Mor O., Read M., and Fried M. p53 in polyoma virus transformed REF52 cells. Oncogene 15 (1997) 3113-3119
9. Illei P.B., Rusch V.W., Zakowski M.F., and Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9 (2003) 2108-2113
10. Xiao G.H., Gallagher R., Shetler J., Skele K., Altomare D.A., Pestell R.G., et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25 (2005) 2384-2394
11. Poulikakos P.I., Xiao G.H., Gallagher R., Jablonski S., Jhanwar S.C., and Testa J.R. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25 (2006) 5960-5968
12. Lopez-Rios F., Chuai S., Flores R., Shimizu S., Ohno T., Wakahara K., et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66 (2006) 2970-2979
13. Xia C., Xu Z., Yuan X., Uematsu K., You L., Li K., et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1 (2002) 687-694
14. Hopkins-Donaldson S., Belyanskaya L.L., Simões-Wüst A.-P., Sigrist B., Kurtz S., Zangemeister-Wittke U., et al. p53-induced apoptosis occurs in the absence of p14ARF in malignant pleural mesothelioma. Neoplasia 8 (2006) 551-559
15. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
16. Ong S.T., and Vogelzang N.J. Chemotherapy in malignant pleural mesothelioma, a review. J Clin Oncol 14 (1996) 1007-1017
17. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16 (2005) 923-927
18. Solheim O.P., Saeter G., Finnanger A.M., and Stenwig A.E. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura, a phase II study. Br J Cancer 65 (1992) 956-960
19. Krarup-Hansen A., and Hansen H.H. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 28 (1991) 319-330
20. Andreopoulou E., Ross P.J., O'Brien M.E., Ford H.E., Priest K., Eisen T., et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 15 (2004) 1406-1412
21. Middleton G.W., Smith I.E., O'Brien M.E., Norton A., Hickish T., Priest K., et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9 (1998) 269-273
22. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
23. Vogelzang NJ, Symanowski J, Rusthoven J, Manegold C, Boyer M, Nguyen B, et al. Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma. Presented at WCLC 2005.
24. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
25. Mbidde E.K., Harland S.J., Calvert A.H., and Smith I.E. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18 (1986) 284-285
26. Raghavan D., Gianoutsos P., Bishop J., Lee J., Young I., Corte P., et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8 (1990) 151-154
27. Vogelzang N.J., Goutsou M., Corson J.M., Suzuki Y., Graziano S., Aisner J., et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27 (1990) 239-242
28. Teicher B.A., Chen V., Shih C., Menon K., Forler P.A., Phares V.G., et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6 (2000) 1016-1023
29. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 (2002) 3533-3544
30. Ceresoli G.L., Zucali P.A., Favaretto A.G., Grossi F., Bidoli P., DelConte G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 (2006) 1443-1448
31. O'Brien M.E., Watkins D., Ryan C., Priest K., Corbishley C., Norton A., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17 (2006) 270-275
32. Fiore D., Baggio V., Sotti G., and Muzzio P.C. Imaging before and after multimodal treatment for malignant pleural mesothelioma. Radiol Med (Torino) 111 (2006) 355-364
33. van den Bogaert D., Pouw E., van Wijhe G., Vernhout R., Surmont V., Hoogsteden H., et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 1 (2006) 25-30
34. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-63 [discussion, p. 63-65]
35. Stahel R., and Weder W. Neoadjuvant chemotherapy in malignant pleural mesothelioma. Lung Cancer 49 (2005) S69-S70
36. Rusch V.W., Rosenzweig K., Venkatraman E., Leon L., Raben A., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
37. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 (2004) 3451-3457
38. Baas P., Boogerd W., Dalesio O., Haringhuizen A., Custers F., and van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48 (2005) 291-296
39. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931